selfworthmatters hashtag performance
#selfworthmatters promotes self-acceptance, confidence, empowerment, mental health, positivity, love, growth, healing, authenticity, value, boundaries, self-care, personal growth, resilience, motivation, encouragement, self-esteem, awareness, mindfulness, inner strength, community, support, authenticity, transformation, self-discovery, joy, pride, acceptance, liberation.
4.9k
“The new move comes as Eli Lilly has also taken action against compounders making copies of tirzepatide, its GLP-1 and GIP agonist sold as Mounjaro for diabetes and Zepbound for obesity in the US.” “Lilly has filed to lend its support to the FDA in a lawsuit filed against the agency by the OFA and FarmaKeio Custom Compounding, which are challenging a decision to remove tirzepatide from the shortages list and bring an end to compounding of the drug.” “As it stands, pharmacies and outsourcing facilities are required to wind down production of tirzepatide by 18th February and 19th March, respectively.” “Lilly has also argued that the presence of compounded products in the supply chain makes it harder for patients to ensure they buy a legally produced version, as the market has been flooded with illicit copies.” "Sometimes these knockoff medicines – which come from places like China and India – are sold by entities that cannot even legally sell them in their own countries," said Patrik Jonsson, president of Lily USA. #zepboundtips #SelfWorthMatters #SelfCareTips #GLP1Journey #SelfCareJourney #ResearchBasedWellness #ObesityIsADisease #mentalhealthmatters #SelfWorthMatters #WomenSupportingWomen #cardiovascularhealth #glp1community #zepboundjourney #fyyyyyyyyyyyyyyyy
4.1k
“On the contrary, emerging evidence indicates that GLP-1RAs might reduce specific symptoms, such as binge eating, in individuals with higher weight who do not have diabetes. Nevertheless, further research is needed to clarify their potential therapeutic role and risks in BED. To date, GLP-1RAs can be considered in people with BED as part of a healthy weight-loss strategy in conjunction with lifestyle changes, but only after binge-eating episodes have significantly decreased and regular eating patterns are well established.”#mentalhealthmatters #SelfCareJourney #GLP1Journey #SelfCareTips #fy #SelfWorthMatters #zepboundtips #WomenSupportingWomen #fypシ #ObesityIsADisease #ResearchBasedWellness #cardiovascularhealth #glp1community #fyp
3.7k
“The seeming endorsement of medications such as Ozempic, Wegovy, Mounjaro and Zepbound from two people who have Trump's ear is likely to be a relief for the pharmaceutical industry following Kennedy's sharp questioning of America's reliance on weight-loss medications. Previously, Kennedy has said that if America paid more for quality food, it would solve the obesity crisis "overnight" -- a statement obesity experts criticized as overly simplistic.” #glp1community #WomenSupportingWomen #cardiovascularhealth #fypシ #GLP1Journey #SelfCareJourney #SelfCareTips #fyyyyyyyyyyyyyyyy #cardiovascularhealth #zepboundjourney #zepboundtips #ResearchBasedWellness #SelfWorthMatters #ObesityIsADisease #fy
3.6k
“List prices for a month's supply of GLP-1s range from about $936 to $1,349 before insurance, which often doesn't pay enough for people to afford the drugs, according to Kaiser Family Foundation research.” “Widespread shortages have prevented some patients from getting prescriptions filled, though the FDA has said the shortages are improving. Meanwhile, pharmacies are introducing compounded alternatives that critics say allow them to skirt regulatory review.” #SelfWorthMatters #SelfCareJourney #ResearchBasedWellness #zepboundtips #SelfCareTips #WomenSupportingWomen #GLP1Journey #glp1community #ObesityIsADisease #cardiovascularhealth #mentalhealthmatters #zepboundjourney #fy
2.9k
“Dr. Cynthia Cox, vice president at KFF (formerly Kaiser Family Foundation), a nonprofit that offers information, analysis and research on health policy, acknowledged the potential health benefits but noted the financial challenge.” "These drugs cost around $500 to $1,000 per month. So, even if they prevent diabetes or heart disease down the road, that potential savings isn't enough to offset the high monthly cost of the drug," she told Newsweek. “According to a KFF analysis, the list price of Ozempic in the United States is $936 per month, more than five times the cost in Japan, where it sells for $169—the second-highest price among the countries studied. Similarly, Wegovy, another medication with the same active ingredient as Ozempic, is roughly four times as expensive in the U.S. ($1,349) compared to Germany ($328).” #SelfCareJourney #SelfCareTips #SelfWorthMatters #cardiovascularhealth #fyyyyyyyyyyyyyyyy #ResearchBasedWellness #glp1community #WomenSupportingWomen #zepboundjourney #zepboundtips #ObesityIsADisease #GLP1Journey #fy #fyp
![“Background: Endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) regulate islet cell function. GLP-1 receptor agonists (GLP-1RAs) have been associated with an elevated risk of acute pancreatitis. Data on the pancreatic safety of tirzepatide (a dual GLP-1 and GIP agonist) and its effects on islet cell function in randomized controlled trials (RCTs) are scarce. Moreover, no meta-analysis has comprehensively examined such effects of tirzepatide.” Methods: “Electronic databases were searched for RCTs with tirzepatide as the intervention and a placebo or active comparator as the control. The primary outcome was adjudication-confirmed pancreatitis; secondary outcomes were the percent changes from baseline in serum pancreatic amylase, lipase, insulin, C-peptide, glucagon, and homeostasis model assessment of insulin resistance (HOMA2-IR).” Results: “Seventeen RCTs with 18 published reports involving 14,645 subjects were analyzed. Over a follow-up duration of 12-72 weeks, tirzepatide had identical risks of pancreatitis to placebo (tirzepatide 5 mg: RR 2.04, 95% CI [0.27-15.69], p = 0.49; 10 mg: RR 0.63, 95% CI [0.08-5.12], p = 0.67; and 15 mg: RR 1.26, 95% CI [0.36-4.98], p = 0.72). Tirzepatide was also associated with comparable risks of pancreatitis to insulin and GLP-1RAs. However, tirzepatide (at all doses) caused greater increases in pancreatic amylase and lipase than placebo and insulin. Individuals on tirzepatide 15 mg and GLP-1RAs had similar risks of having increased lipase levels. The percent reductions in fasting insulin were greater with tirzepatide 10 and 15 mg than with placebo. All doses of tirzepatide caused greater percent reductions in fasting insulin, C-peptide, and glucagon than GLP-1RAs. Compared to placebo and GLP-1RAs, the percent reductions in HOMA2-IR were greater with all doses of tirzepatide.” #glp1community #ObesityIsADisease #zepboundtips #WomenSupportingWomen #GLP1Journey #ResearchBasedWellness #cardiovascularhealth #SelfWorthMatters #zepboundjourney #SelfCareJourney #SelfCareTips #mentalhealthmatters #fy](/_next/image?url=https%3A%2F%2Fdz59t6y8jvnrr.cloudfront.net%2Fvideo%2F7452928247190408479.jpg&w=1080&q=75)
2.8k
“Background: Endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) regulate islet cell function. GLP-1 receptor agonists (GLP-1RAs) have been associated with an elevated risk of acute pancreatitis. Data on the pancreatic safety of tirzepatide (a dual GLP-1 and GIP agonist) and its effects on islet cell function in randomized controlled trials (RCTs) are scarce. Moreover, no meta-analysis has comprehensively examined such effects of tirzepatide.” Methods: “Electronic databases were searched for RCTs with tirzepatide as the intervention and a placebo or active comparator as the control. The primary outcome was adjudication-confirmed pancreatitis; secondary outcomes were the percent changes from baseline in serum pancreatic amylase, lipase, insulin, C-peptide, glucagon, and homeostasis model assessment of insulin resistance (HOMA2-IR).” Results: “Seventeen RCTs with 18 published reports involving 14,645 subjects were analyzed. Over a follow-up duration of 12-72 weeks, tirzepatide had identical risks of pancreatitis to placebo (tirzepatide 5 mg: RR 2.04, 95% CI [0.27-15.69], p = 0.49; 10 mg: RR 0.63, 95% CI [0.08-5.12], p = 0.67; and 15 mg: RR 1.26, 95% CI [0.36-4.98], p = 0.72). Tirzepatide was also associated with comparable risks of pancreatitis to insulin and GLP-1RAs. However, tirzepatide (at all doses) caused greater increases in pancreatic amylase and lipase than placebo and insulin. Individuals on tirzepatide 15 mg and GLP-1RAs had similar risks of having increased lipase levels. The percent reductions in fasting insulin were greater with tirzepatide 10 and 15 mg than with placebo. All doses of tirzepatide caused greater percent reductions in fasting insulin, C-peptide, and glucagon than GLP-1RAs. Compared to placebo and GLP-1RAs, the percent reductions in HOMA2-IR were greater with all doses of tirzepatide.” #glp1community #ObesityIsADisease #zepboundtips #WomenSupportingWomen #GLP1Journey #ResearchBasedWellness #cardiovascularhealth #SelfWorthMatters #zepboundjourney #SelfCareJourney #SelfCareTips #mentalhealthmatters #fy
2.8k
“A disproportionality analysis detects significant associations between drugs and adverse events. However, the FAERS can also provide information on inverse associations that may serve to identify potential drug repurposing avenues.” “Shirani and the team analyzed anti-diabetic and non-diabetic drugs with weight loss-inducing effects. Anti-diabetic medications included the glucagon-like peptide-1 (GLP-1) receptor agonists semaglutide (marketed as Ozempic and Rybelsus for diabetes and Wegovy for weight loss), tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss), Trulicity (dulaglutide), and liraglutide (available as Saxenda and Victoza); the sodium-glucose cotransporter-2 (SGLT-2) inhibitors Jardiance (empagliflozin), Invokana (canagliflozin), and Farxiga (dapagliflozin); and the biguanide metformin.” #SelfCareTips #mentalhealthmatters #fy #WomenSupportingWomen #glp1community #SelfWorthMatters #fyyyyyyyyyyyyyyyy #ObesityIsADisease #zepboundjourney #GLP1Journey #SelfCareJourney #ResearchBasedWellness #cardiovascularhealth #zepboundtips #fyp
2.5k
“From the pioneering moment in 1987 when the insulinotropic effect of glucagon-like peptide 1 (GLP-1) was first demonstrated in humans, to today's pharmaceutical gold rush for GLP-1-based treatments of obesity, the journey of GLP-1 pharmacology has been nothing short of extraordinary. The sequential conceptual developments of long-acting GLP-1 receptor (GLP-1R) mono-agonists, GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonists, and GLP-1R/GIPR/glucagon receptor (GcgR) triple agonists, have led to profound body weight-lowering capacities, with benefits that extend past obesity and towards obesity-associated diseases. The GLP-1R/GIPR dual-agonist tirzepatide has demonstrated a remarkable 23% body weight reduction in individuals with obesity over 72 weeks, eclipsing the average result achieved by certain types of bariatric surgery. Meanwhile, the GLP-1R/GIPR/GcgR triple-agonist retatrutide achieves similar body weight loss (∼25%) in just two-thirds of the time, potentially surpassing the efficacy of Roux-en-Y gastric bypass. These remarkable achievements rightfully raise the question whether and why there is still need for novel anti-obesity medications (AOMs) in the future.” #ObesityIsADisease #ResearchBasedWellness #fypシ #SelfCareTips #SelfWorthMatters #glp1community #cardiovascularhealth #fy #mentalhealthmatters #SelfCareJourney #GLP1Journey #zepboundtips #zepboundjourney #fyp
2.3k
“To test that theory, using body mass index (BMI) as a guide, the team reviewed data collected from three sources: a group of both overweight/obese and normal-weight patients who underwent surgery for non-small cell lung cancer (NSCLC); a group of overweight/obese and normal-weight patients with NSCLC who received a type of immunotherapy called an immune checkpoint inhibitor; and preclinical lung cancer models. Published recently in the Journal of the National Cancer Institute, their study revealed: Metformin’s anticancer effects were seen only in the context of overweight/obesity. Overweight patients who took metformin and underwent surgery experienced longer periods during which the disease did not grow worse. In preclinical lung cancer models, metformin slowed tumor growth and reversed obesity-caused suppression of the immune system. In the same preclinical models, treatment with a combination of metformin and an immune checkpoint inhibitor called an anti-PD1 antibody therapy, which works by “releasing the brakes” on the immune system, resulted in even better tumor control — but again, only in obese models. Drug may strengthen immune system against cancer” “Joseph Barbi, PhD, Assistant Professor of Oncology in Roswell Park’s Department of Immunology and co-senior author with Dr. Yendamuri on the new study, adds that the team’s findings show that in obese or overweight patients, metformin appears to shift the balance between biological processes that suppress the immune system — preventing it from fighting cancer effectively — to those that actively kill tumors.” “Dr. Barbi says he hopes this research will inspire other investigators to launch additional studies to fully explore metformin’s potential. “We believe our findings provide a rationale for testing drug combinations that could prevent or treat lung cancer more effectively in this growing pool of patients.” #metformin #zepboundtips #SelfCareTips #fy #mentalhealthmatters #ObesityIsADisease #SelfWorthMatters #zepboundjourney #WomenSupportingWomen #GLP1Journey #ResearchBasedWellness #glp1community #cardiovascularhealth #SelfCareJourney #fyyyyyyyyyyyyyyyy
2.2k
“If successful in later stage trials, the company will be entering into a market space currently dominated by Novo Nordisk’s Weygovy and Eli Lilly’s Zepbound with the new entrant having the significant advantage of the potential for monthly a dosing regimen where as Zepbound and Weygovy. The company is preparing for Phase III trials set to begin this year.” #ResearchBasedWellness #SelfCareTips #GLP1Journey #glp1community #zepboundjourney #zepboundtips #WomenSupportingWomen #ObesityIsADisease #cardiovascularhealth #mentalhealthmatters #SelfWorthMatters #SelfCareJourney #fy
1.9k
“Dr. Bisher Mustafa of the Marshall Health Obesity Clinic in Huntington said there’s a certain irony to waiting “until people have diabetes to start the medication.” “The idea is to try to prevent diabetes from happening from the beginning,” he said. “PEIA Director Brian Cunningham said GLP-1s, which the state began offering for weight loss in 2019, cost the program around $53 million last fiscal year — about 20% of what PEIA spends on drugs.” “The cost of the GLP-1s was cited as a reason for 14% premium hikes for state employees, as well as a 16% increase for county employees and a 12% bump in costs for retirees. Increases will go into effect in July, according to the insurance agency, which covers 150,000 government workers, 56,000 retirees and their dependents.” “That’s frustrated some PEIA members who feel they are unfairly shouldering the cost burden for a medication they don’t use. Ashley Peggs, a Kanawha County teacher who doesn’t use GLP-1 drugs, said her heart sank when she saw how much the plan was spending on the medicines during a public hearing about the proposed premium increases.” “She said the agency had just denied coverage for a spinal procedure for a condition threatening her ability to walk.” “So somebody else being skinny is more important than the fact that I literally may not be able to continue teaching until I retire without a wheelchair?” said Peggs, 35, at the public hearing. “Some taking the drugs for diabetes — like the vast majority of state employees on GLP-1s — expressed frustration that they haven’t even been able to access Ozempic consistently because of shortages.” “What’s going to be cheaper: pay for that medication or for me to lose a leg to gangrene like my grandmother did?” said Michael Kimball, 42, who takes the drug for diabetes. “Year after year, the burden is put on the back of the working man and we’re getting a little tired of it.” “Osborn described Wegovy as a breakthrough recommended by her provider after she’d tried for years to lose weight any way she could. She’s also been able to halve the amount of rheumatoid arthritis medication she takes and she’s seen back pain and her sciatica almost eradicated.” #GLP1Journey #zepboundjourney #zepboundtips #mentalhealthmatters #SelfWorthMatters #fyyyyyyyyyyyyyyyy #SelfCareJourney #WomenSupportingWomen #ObesityIsADisease #fy #cardiovascularhealth #SelfCareTips #ResearchBasedWellness #fyp #glp1community #
1.8k
“This is the reality of obesity, a condition that drives chronic disease but is met with barriers to care at every turn. Obesity isn't a mere lifestyle choice or lack of willpower; it's a complex, chronic disease that heightens the risk of many of the most common chronic conditions: diabetes, heart disease, hypertension, osteoarthritis, and more.” “Yet, despite the power of GLP-1 anti-obesity medications to reduce these risks, many insurers continue to deny coverage, leaving millions of Americans to fend for themselves.” “Obesity: The Most Costly and Preventable Health Risk Factor” #mentalhealthmatters #WomenSupportingWomen #fy #SelfCareTips #glp1community #SelfWorthMatters #fyyyyyyyyyyyyyyyy #fyp #GLP1Journey #zepboundjourney #ObesityIsADisease #SelfCareJourney #fypシ #ResearchBasedWellness #zepboundtips
1.8k
If you constantly feel like you’re walking on eggshells in a relationship, that’s not healthy communication—it’s fear. 💔 Healthy relationships allow you to express yourself openly, without the anxiety of triggering conflict or criticism. You deserve connections where you feel safe to be heard, understood, and valued—not silenced or second-guessed. . #healthycommunication #mentalhealthsupport #HealthyRelationships #HealingJourney #selfworthmatters #safespace #MentalHealthAwarenes #relationshipadvice
1.7k
“What Does GLP-1-Friendly Mean?” “According to the press releases put out by both companies, GLP-1-friendly foods are those that are high in fiber and protein. There are good reasons they’re focusing on these two nutrients.” “First, when you lose weight, especially if the weight loss is rapid, as is often the case with GLP-1s, you also lose muscle mass. This is especially true if you’re not strength-training or eating enough protein while losing weight.” “Because appetite is reduced on these drugs, it might be difficult to get enough of all the nutrients you need for good health and muscle maintenance, including protein. But you don’t want to lose muscle mass while losing weight. It isn’t just that you could become weaker physically—muscle is metabolically active tissue that uses calories, and you want to keep as much of it as possible.” “The other problem with losing so much muscle mass is that it can throw off your body composition, or how much fat and lean tissue you have. So while the goal of weight loss is really fat loss, if you’re not eating enough protein and engaging in strength training, you will lose weight, but not in the way that you want. And ultimately, you could end up with a higher ratio of body fat to muscle, which is undesirable from a whole-health perspective.” #ResearchBasedWellness #ObesityIsADisease #zepboundtips #WomenSupportingWomen #SelfWorthMatters #mentalhealthmatters #cardiovascularhealth #glp1community #GLP1Journey #SelfCareTips #zepboundjourney #SelfCareJourney #fyp
1.6k
“Data on almost 17 million adults nationwide showed the obesity rate -- which has been rising for years -- fell from 46.2% of adults in 2021 to 45.6% in 2023, Harvard University researchers report.” “Obesity was defined as having a body mass index (BMI) of 30 or above.” “At the same time, the use of GLP-1 medications like Wegovy and Zepbound has surged, although the researchers said it's not possible to confirm a cause-and-effect relationship between the trends.” #cardiovascularhealth #GLP1Journey #SelfCareJourney #zepboundtips #WomenSupportingWomen #glp1community #fypシ #SelfCareTips #ObesityIsADisease #fy #zepboundjourney #zepboundtips #ResearchBasedWellness #SelfWorthMatters #fyyyyyyyyyyyyyyyy
1.6k
“Critics have raised concerns about the ethics of off-label use, the affordability gap that makes these drugs inaccessible to many, and the long-term implications of relying on medication over lifestyle adjustments. With public demand continuing to climb, questions about the future of these drugs are more relevant than ever.” #fy #mentalhealthmatters #SelfWorthMatters #zepboundtips #SelfCareTips #ObesityIsADisease #WomenSupportingWomen #zepboundjourney #GLP1Journey #ResearchBasedWellness #SelfCareJourney #glp1community #cardiovascularhealth #fypシ
1.5k
And this is going to upset people who want it to only be because of weightloss. I don’t actually get the why on that. #mentalhealthmatters #WomenSupportingWomen #SelfCareTips #ObesityIsADisease #fy #SelfWorthMatters #glp1community #zepboundjourney #GLP1Journey #SelfCareJourney #ResearchBasedWellness #cardiovascularhealth #glp1journey #fypシ
1.3k
“The investigators looked at late-onset seizures and epilepsy (defined as diagnosed after age 55 years) in three classes of glucose-lowering drugs: GLP-1 RAs, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose transport protein 2 (SGLT2) inhibitors.” “While not “brand new,” these glucose-lowering drugs were introduced between 2000 and 2010 and represent “modern advances” compared with older medicines such metformin and sulfonylureas, said Sindhu. He added these “newer” agents are more apt to decrease neuroinflammation.” #glp1community #GLP1Journey #SelfCareJourney #WomenSupportingWomen #ResearchBasedWellness #cardiovascularhealth #ObesityIsADisease #zepboundtips #fypシ #SelfWorthMatters #fyp #SelfCareTips #zepboundjourney #fy
![“Indeed, the sheer amount of weight loss is one factor that determines how much muscle loss you’re likely to experience on a GLP-1, agrees Ian J. Neeland, MD, director of cardiovascular prevention and co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute, who has also authored studies on the subject. “People who lose more weight will be at risk for losing more muscle—it goes in a linear fashion,” Dr. Neeland explains. “Although data is sparse, since people lose so much more weight with GLP-1 medications compared with diet and exercise alone, the amount of muscle loss is more for [those on these] medications.”#ObesityIsADisease #glp1journey #mentalhealthmatters #SelfCareTips #fyp #zepboundjourney #SelfCareJourney #cardiovascularhealth #fyyyyyyyyyyyyyyyy #WomenSupportingWomen #zepboundtips #SelfWorthMatters #ResearchBasedWellness #fypシ](/_next/image?url=https%3A%2F%2Fdz59t6y8jvnrr.cloudfront.net%2Fvideo%2F7453253500835859743.jpg&w=1080&q=75)
1.2k
“Indeed, the sheer amount of weight loss is one factor that determines how much muscle loss you’re likely to experience on a GLP-1, agrees Ian J. Neeland, MD, director of cardiovascular prevention and co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute, who has also authored studies on the subject. “People who lose more weight will be at risk for losing more muscle—it goes in a linear fashion,” Dr. Neeland explains. “Although data is sparse, since people lose so much more weight with GLP-1 medications compared with diet and exercise alone, the amount of muscle loss is more for [those on these] medications.”#ObesityIsADisease #glp1journey #mentalhealthmatters #SelfCareTips #fyp #zepboundjourney #SelfCareJourney #cardiovascularhealth #fyyyyyyyyyyyyyyyy #WomenSupportingWomen #zepboundtips #SelfWorthMatters #ResearchBasedWellness #fypシ
![“Worldwide, 43% of adults were overweight in 2022 and the number may escalate to 4 billion by 2035. Obesity increases all-cause mortality due to increased cardiovascular disease and diabetes in affected individuals,” Thennati said during the presentation. “Utreglutide is a novel analog with potent G-protein bias, long-acting agonist activity at the glucagon-like peptide-1 receptor. In the phase 1 study, we did observe that in one single dose that weight loss of about 3 kg persisted for about 3 more weeks [after treatment discontinuation]. That’s the something which was unique with this product.” #GLP1Journey #cardiovascularhealth #glp1community #SelfCareJourney #WomenSupportingWomen #zepboundtips #ObesityIsADisease #ResearchBasedWellness #SelfCareTips #SelfWorthMatters #fypシ](/_next/image?url=https%3A%2F%2Fdz59t6y8jvnrr.cloudfront.net%2Fvideo%2F7449417332260113695.jpg&w=1080&q=75)
1.2k
“Worldwide, 43% of adults were overweight in 2022 and the number may escalate to 4 billion by 2035. Obesity increases all-cause mortality due to increased cardiovascular disease and diabetes in affected individuals,” Thennati said during the presentation. “Utreglutide is a novel analog with potent G-protein bias, long-acting agonist activity at the glucagon-like peptide-1 receptor. In the phase 1 study, we did observe that in one single dose that weight loss of about 3 kg persisted for about 3 more weeks [after treatment discontinuation]. That’s the something which was unique with this product.” #GLP1Journey #cardiovascularhealth #glp1community #SelfCareJourney #WomenSupportingWomen #zepboundtips #ObesityIsADisease #ResearchBasedWellness #SelfCareTips #SelfWorthMatters #fypシ
1.1k
start an influencer campaign that drives genuine engagement
Technology
Fastest Growing